Сравнение
Elamipretide vs. Teriparatid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
736992-21-5
52232-67-4
Молекулярная масса
639.8 g/mol
4117.8 g/mol
Период полувыведения
нет данных
1 h
Последовательность
D-Arg-Dmt-Lys-Phe-NH2Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-PheМеханизм действия
Elamipretide
Elamipretide is a cell-permeable tetrapeptide with alternating aromatic and basic residues that selectively concentrates on cardiolipin — a phospholipid found almost exclusively in the inner mitochondrial membrane that is important for cristae curvature and the organisation of the respiratory-chain complexes. By binding cardiolipin, elamipretide is proposed to stabilise cristae architecture, support electron transport and ATP production, and reduce the formation of reactive oxygen species. These mechanistic models derive largely from cell and animal models and biophysical work; the extent to which they explain clinical efficacy in humans is, given the mixed trial results, a matter of ongoing research.
Teriparatid
Teriparatide corresponds to the biologically active first 34 amino acids of human parathyroid hormone and binds the PTH-1 receptor on bone and kidney cells. The literature describes that intermittent receptor activation preferentially stimulates the activity of bone-forming osteoblasts, whereas continuously elevated PTH exposure (as in hyperparathyroidism) tends to favor bone resorption. This time-dependent difference is regarded as the mechanistic basis for the bone-anabolic effect observed in studies.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
4
из них на людях
4
4
Зафиксированные эффекты
4
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
1
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Elamipretide and Teriparatid?
- Elamipretide is classified as "Исследования (прочее)", while Teriparatid is classified as "Исследования (прочее)". Elamipretide: Elamipretide (SS-31, MTP-131, formerly Bendavia) is a synthetic, mitochondria-targeting tetrapeptide (sequence D-Arg-Dmt-Lys-Phe-NH2) that binds cardiolipin on the inner mitochondrial membrane and is proposed to stabilise cristae structure and support mitochondrial bioenergetics. It was investigated clinically by Stealth BioTherapeutics across several indications, including primary mitochondrial myopathy, Barth syndrome, heart failure, and dry age-related macular degeneration (geographic atrophy). The trial record is mixed, with several pivotal studies missing their primary endpoints. In September 2025 elamipretide (brand name Forzinity) received accelerated FDA approval in the United States solely for the ultra-rare Barth syndrome; for all other investigated indications it remains investigational and it is not approved as a medicine outside the United States. Teriparatid: Teriparatide is the recombinant N-terminal fragment 1-34 of human parathyroid hormone (PTH). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis. Unlike antiresorptive agents, studies attribute to it an effect that stimulates new bone formation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Elamipretide or Teriparatid?
- The highest available evidence level is "РКИ на людях" for Elamipretide and "РКИ на людях" for Teriparatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Elamipretide and Teriparatid in Germany and the United States?
- Германия: Elamipretide — Не одобрено, Teriparatid — Рецептурный. США: Elamipretide — Рецептурный, Teriparatid — Рецептурный. These are factual summaries with source and review date on the individual pages.